Notably, CXCL9 is preferentially expressed in primary cDC1s (Figure S3D) and plays a major role in cDC1-mediated priming of tumor-specific T cell responses (de Mingo Pulido et al., 2018, Spranger et al., 2017). Here, CXCL9 is linked to neoplasm.